263 related articles for article (PubMed ID: 34111452)
1. Therapeutic options for CTLA-4 insufficiency.
Egg D; Rump IC; Mitsuiki N; Rojas-Restrepo J; Maccari ME; Schwab C; Gabrysch A; Warnatz K; Goldacker S; Patiño V; Wolff D; Okada S; Hayakawa S; Shikama Y; Kanda K; Imai K; Sotomatsu M; Kuwashima M; Kamiya T; Morio T; Matsumoto K; Mori T; Yoshimoto Y; Dybedal I; Kanariou M; Kucuk ZY; Chapdelaine H; Petruzelkova L; Lorenz HM; Sullivan KE; Heimall J; Moutschen M; Litzman J; Recher M; Albert MH; Hauck F; Seneviratne S; Pachlopnik Schmid J; Kolios A; Unglik G; Klemann C; Snapper S; Giulino-Roth L; Svaton M; Platt CD; Hambleton S; Neth O; Gosse G; Reinsch S; Holzinger D; Kim YJ; Bakhtiar S; Atschekzei F; Schmidt R; Sogkas G; Chandrakasan S; Rae W; Derfalvi B; Marquart HV; Ozen A; Kiykim A; Karakoc-Aydiner E; Králíčková P; de Bree G; Kiritsi D; Seidel MG; Kobbe R; Dantzer J; Alsina L; Armangue T; Lougaris V; Agyeman P; Nyström S; Buchbinder D; Arkwright PD; Grimbacher B
J Allergy Clin Immunol; 2022 Feb; 149(2):736-746. PubMed ID: 34111452
[TBL] [Abstract][Full Text] [Related]
2. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects.
Schwab C; Gabrysch A; Olbrich P; Patiño V; Warnatz K; Wolff D; Hoshino A; Kobayashi M; Imai K; Takagi M; Dybedal I; Haddock JA; Sansom DM; Lucena JM; Seidl M; Schmitt-Graeff A; Reiser V; Emmerich F; Frede N; Bulashevska A; Salzer U; Schubert D; Hayakawa S; Okada S; Kanariou M; Kucuk ZY; Chapdelaine H; Petruzelkova L; Sumnik Z; Sediva A; Slatter M; Arkwright PD; Cant A; Lorenz HM; Giese T; Lougaris V; Plebani A; Price C; Sullivan KE; Moutschen M; Litzman J; Freiberger T; van de Veerdonk FL; Recher M; Albert MH; Hauck F; Seneviratne S; Pachlopnik Schmid J; Kolios A; Unglik G; Klemann C; Speckmann C; Ehl S; Leichtner A; Blumberg R; Franke A; Snapper S; Zeissig S; Cunningham-Rundles C; Giulino-Roth L; Elemento O; Dückers G; Niehues T; Fronkova E; Kanderová V; Platt CD; Chou J; Chatila TA; Geha R; McDermott E; Bunn S; Kurzai M; Schulz A; Alsina L; Casals F; Deyà-Martinez A; Hambleton S; Kanegane H; Taskén K; Neth O; Grimbacher B
J Allergy Clin Immunol; 2018 Dec; 142(6):1932-1946. PubMed ID: 29729943
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic modalities and clinical outcomes in a large cohort with LRBA deficiency and CTLA4 insufficiency.
Taghizade N; Babayeva R; Kara A; Karakus IS; Catak MC; Bulutoglu A; Haskologlu ZS; Akay Haci I; Tunakan Dalgic C; Karabiber E; Bilgic Eltan S; Yorgun Altunbas M; Sefer AP; Sezer A; Kokcu Karadag SI; Arik E; Karali Z; Ozhan Kont A; Tuzer C; Karaman S; Mersin SS; Kasap N; Celik E; Kocacik Uygun DF; Aydemir S; Kiykim A; Aydogmus C; Ozek Yucel E; Celmeli F; Karatay E; Bozkurtlar E; Demir S; Metin A; Karaca NE; Kutukculer N; Aksu G; Guner SN; Keles S; Reisli I; Kendir Demirkol Y; Arikoglu T; Gulez N; Genel F; Kilic SS; Aytekin C; Keskin O; Yildiran A; Ozcan D; Altintas DU; Ardeniz FO; Dogu EF; Ikinciogullari KA; Karakoc-Aydiner E; Ozen A; Baris S
J Allergy Clin Immunol; 2023 Dec; 152(6):1634-1645. PubMed ID: 37595759
[TBL] [Abstract][Full Text] [Related]
4. What did we learn from CTLA-4 insufficiency on the human immune system?
Mitsuiki N; Schwab C; Grimbacher B
Immunol Rev; 2019 Jan; 287(1):33-49. PubMed ID: 30565239
[TBL] [Abstract][Full Text] [Related]
5. AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy.
Lo B; Zhang K; Lu W; Zheng L; Zhang Q; Kanellopoulou C; Zhang Y; Liu Z; Fritz JM; Marsh R; Husami A; Kissell D; Nortman S; Chaturvedi V; Haines H; Young LR; Mo J; Filipovich AH; Bleesing JJ; Mustillo P; Stephens M; Rueda CM; Chougnet CA; Hoebe K; McElwee J; Hughes JD; Karakoc-Aydiner E; Matthews HF; Price S; Su HC; Rao VK; Lenardo MJ; Jordan MB
Science; 2015 Jul; 349(6246):436-40. PubMed ID: 26206937
[TBL] [Abstract][Full Text] [Related]
6. Immune dysregulation syndrome with de novo CTLA4 germline mutation responsive to abatacept therapy.
Ureshino H; Koarada S; Kamachi K; Yoshimura M; Yokoo M; Kubota Y; Ando T; Ichinohe T; Morio T; Kimura S
Int J Hematol; 2020 Jun; 111(6):897-902. PubMed ID: 31993940
[TBL] [Abstract][Full Text] [Related]
7. Clinical Phenotypes and Immunological Characteristics of 18 Egyptian LRBA Deficiency Patients.
Meshaal S; El Hawary R; Adel R; Abd Elaziz D; Erfan A; Lotfy S; Hafez M; Hassan M; Johnson M; Rojas-Restrepo J; Gamez-Diaz L; Grimbacher B; Shoman W; Abdelmeguid Y; Boutros J; Galal N; El-Guindy N; Elmarsafy A
J Clin Immunol; 2020 Aug; 40(6):820-832. PubMed ID: 32506362
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of LRBA deficiency in 76 patients after various treatment modalities as evaluated by the immune deficiency and dysregulation activity (IDDA) score.
Tesch VK; Abolhassani H; Shadur B; Zobel J; Mareika Y; Sharapova S; Karakoc-Aydiner E; Rivière JG; Garcia-Prat M; Moes N; Haerynck F; Gonzales-Granado LI; Santos Pérez JL; Mukhina A; Shcherbina A; Aghamohammadi A; Hammarström L; Dogu F; Haskologlu S; İkincioğulları AI; Köstel Bal S; Baris S; Kilic SS; Karaca NE; Kutukculer N; Girschick H; Kolios A; Keles S; Uygun V; Stepensky P; Worth A; van Montfrans JM; Peters AMJ; Meyts I; Adeli M; Marzollo A; Padem N; Khojah AM; Chavoshzadeh Z; Avbelj Stefanija M; Bakhtiar S; Florkin B; Meeths M; Gamez L; Grimbacher B; Seppänen MRJ; Lankester A; Gennery AR; Seidel MG;
J Allergy Clin Immunol; 2020 May; 145(5):1452-1463. PubMed ID: 31887391
[TBL] [Abstract][Full Text] [Related]
9. Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations.
Schubert D; Bode C; Kenefeck R; Hou TZ; Wing JB; Kennedy A; Bulashevska A; Petersen BS; Schäffer AA; Grüning BA; Unger S; Frede N; Baumann U; Witte T; Schmidt RE; Dueckers G; Niehues T; Seneviratne S; Kanariou M; Speckmann C; Ehl S; Rensing-Ehl A; Warnatz K; Rakhmanov M; Thimme R; Hasselblatt P; Emmerich F; Cathomen T; Backofen R; Fisch P; Seidl M; May A; Schmitt-Graeff A; Ikemizu S; Salzer U; Franke A; Sakaguchi S; Walker LSK; Sansom DM; Grimbacher B
Nat Med; 2014 Dec; 20(12):1410-1416. PubMed ID: 25329329
[TBL] [Abstract][Full Text] [Related]
10. Case report: Challenges in immune reconstitution following hematopoietic stem cell transplantation for CTLA-4 insufficiency-like primary immune regulatory disorders.
Margarit-Soler A; Deyà-Martínez À; Canizales JT; Vlagea A; García-García A; Marsal J; Del Castillo MT; Planas S; Simó S; Esteve-Sole A; Grande MS; Badell I; Tarrats MR; Fernández-Avilés F; Alsina L
Front Immunol; 2022; 13():1070068. PubMed ID: 36636328
[TBL] [Abstract][Full Text] [Related]
11. Underlying CTLA4 Deficiency in a Patient With Juvenile Idiopathic Arthritis and Autoimmune Lymphoproliferative Syndrome Features Successfully Treated With Abatacept-A Case Report.
Mazzoni M; Dell'Orso G; Grossi A; Ceccherini I; Viola S; Terranova P; Micalizzi C; Guardo D; Massaccesi E; Palmisani E; Calvillo M; Fioredda F; Malattia C; Dufour C; Ravelli A; Miano M
J Pediatr Hematol Oncol; 2021 Nov; 43(8):e1168-e1172. PubMed ID: 33625086
[TBL] [Abstract][Full Text] [Related]
12. Different Apples, Same Tree: Visualizing Current Biological and Clinical Insights into CTLA-4 Insufficiency and LRBA and DEF6 Deficiencies.
Gámez-Díaz L; Seidel MG
Front Pediatr; 2021; 9():662645. PubMed ID: 33996698
[TBL] [Abstract][Full Text] [Related]
13. Abatacept for treatment-refractory pediatric CTLA4-haploinsufficiency.
Lanz AL; Riester M; Peters P; Schwerd T; Lurz E; Hajji MS; Rohlfs M; Ley-Zaporozhan J; Walz C; Kotlarz D; Klein C; Albert MH; Hauck F
Clin Immunol; 2021 Aug; 229():108779. PubMed ID: 34116213
[TBL] [Abstract][Full Text] [Related]
14. The ABACHAI clinical trial protocol: Safety and efficacy of abatacept (s.c.) in patients with CTLA-4 insufficiency or LRBA deficiency: A non controlled phase 2 clinical trial.
Krausz M; Uhlmann A; Rump IC; Ihorst G; Goldacker S; Sogkas G; Posadas-Cantera S; Schmidt R; Feißt M; Alsina L; Dybedal I; Recher M; Warnatz K; Grimbacher B
Contemp Clin Trials Commun; 2022 Dec; 30():101008. PubMed ID: 36262801
[TBL] [Abstract][Full Text] [Related]
15. CTLA4 Message Reflects Pathway Disruption in Monogenic Disorders and Under Therapeutic Blockade.
Garcia-Perez JE; Baxter RM; Kong DS; Tobin R; McCarter M; Routes JM; Verbsky J; Jordan MB; Dutmer CM; Hsieh EWY
Front Immunol; 2019; 10():998. PubMed ID: 31156616
[TBL] [Abstract][Full Text] [Related]
16. Comparing the levels of CTLA-4-dependent biological defects in patients with LRBA deficiency and CTLA-4 insufficiency.
Catak MC; Akcam B; Bilgic Eltan S; Babayeva R; Karakus IS; Akgun G; Baser D; Bulutoglu A; Bayram F; Kasap N; Kiykim A; Hancioglu G; Kokcu Karadag SI; Kendir Demirkol Y; Ozen S; Cekic S; Ozcan D; Edeer Karaca N; Sasihuseyinoglu AS; Cansever M; Ozek Yucel E; Tamay Z; Altintas DU; Aydogmus C; Celmeli F; Cokugras H; Gulez N; Genel F; Metin A; Guner SN; Kutukculer N; Keles S; Reisli I; Kilic SS; Yildiran A; Karakoc-Aydiner E; Lo B; Ozen A; Baris S
Allergy; 2022 Oct; 77(10):3108-3123. PubMed ID: 35491430
[TBL] [Abstract][Full Text] [Related]
17. Murine LRBA deficiency causes CTLA-4 deficiency in Tregs without progression to immune dysregulation.
Burnett DL; Parish IA; Masle-Farquhar E; Brink R; Goodnow CC
Immunol Cell Biol; 2017 Oct; 95(9):775-788. PubMed ID: 28611475
[TBL] [Abstract][Full Text] [Related]
18. Increased Risk for Malignancies in 131 Affected
Egg D; Schwab C; Gabrysch A; Arkwright PD; Cheesman E; Giulino-Roth L; Neth O; Snapper S; Okada S; Moutschen M; Delvenne P; Pecher AC; Wolff D; Kim YJ; Seneviratne S; Kim KM; Kang JM; Ojaimi S; McLean C; Warnatz K; Seidl M; Grimbacher B
Front Immunol; 2018; 9():2012. PubMed ID: 30250467
[No Abstract] [Full Text] [Related]
19. Multifocal gastric adenocarcinoma in a patient with LRBA deficiency.
Bratanič N; Kovač J; Pohar K; Trebušak Podkrajšek K; Ihan A; Battelino T; Avbelj Stefanija M
Orphanet J Rare Dis; 2017 Jul; 12(1):131. PubMed ID: 28720148
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint deficiencies and autoimmune lymphoproliferative syndromes.
Gámez-Díaz L; Grimbacher B
Biomed J; 2021 Aug; 44(4):400-411. PubMed ID: 34384744
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
